Abstract: The PROMIS Pain Interference short forms are responsive to change. Their responsiveness are comparable to legacy pain measures. Responsiveness may vary based on the sample and the direction of change.
ABSTRACTThe PROMIS Pain Interference (PROMIS-PI) scales are reliable and publicly accessible; however, little is known about how responsive they are to detect change in clinical trials and how their responsiveness compares to legacy measures. The study purpose was to evaluate responsiveness for the PROMIS-PI … Show more
“…To our knowledge, this is the first study that validates the psychometric properties and feasibility of applying these PROMIS and legacy instruments in an older Veteran population with cLBP. Our results are consistent with literature focused on patients with chronic back pain, where PROMIS instruments correlated well with legacy measures [37][38][39][40]. In a retrospective review of an outcomes database, PROMIS Pain Interference, Physical Function, and Pain Intensity instruments correlated strongly with traditional disability measures in patients with back and neck pain [41].…”
Background
Chronic low back pain (cLBP) results in significant physical, psycho-social and socioeconomic burden. Identifying efficient and reliable patient reported outcome measures is critical for research and clinical purposes. The NIH’s Patient Reported Outcomes Measurement Information System (PROMIS) instruments have not been compared to validated “legacy” instruments in older adults with cLBP. This study evaluates construct (convergent and discriminant) validity and time to complete (TTC) PROMIS as compared to legacy instruments.
Methods
We enrolled older Veterans (age 60+) with cLBP with/without leg pain scheduled for lumbar epidural steroid injections. Subjects completed PROMIS computer adaptive test item banks and corresponding legacy instruments in the following domains: pain intensity, interference, and behavior; functional status; depression and anxiety; fatigue; sleep and social functioning. Convergent and discriminant validity between PROMIS and legacy instruments was evaluated using Spearman rank order correlations; Mann-Whitney U tests compared TTC.
Results
Of the 71 Veterans recruited, the median (IQR) age was 67 (63–71) years old, 94% were men, 76% were White, 17% Black, and 96% were Non-Hispanic. Spearman correlations between PROMIS and legacy instruments showed moderate to very strong convergent validity in all domains (r = 0.4–1.0), except for social functioning and pain behavior (PROMIS Pain Behavior with Fear Avoidance Belief Questionnaire). The total median TTC for all PROMIS items was significantly shorter than legacy items, 8 min 50 s vs 29 min 14 s respectively, p < 0.001.
Conclusions
Given time efficiency of using PROMIS, along with strong construct validity, PROMIS instruments are a practical choice for measuring multidimensional PROs in older Veterans with cLBP for both research and clinical purposes.
“…To our knowledge, this is the first study that validates the psychometric properties and feasibility of applying these PROMIS and legacy instruments in an older Veteran population with cLBP. Our results are consistent with literature focused on patients with chronic back pain, where PROMIS instruments correlated well with legacy measures [37][38][39][40]. In a retrospective review of an outcomes database, PROMIS Pain Interference, Physical Function, and Pain Intensity instruments correlated strongly with traditional disability measures in patients with back and neck pain [41].…”
Background
Chronic low back pain (cLBP) results in significant physical, psycho-social and socioeconomic burden. Identifying efficient and reliable patient reported outcome measures is critical for research and clinical purposes. The NIH’s Patient Reported Outcomes Measurement Information System (PROMIS) instruments have not been compared to validated “legacy” instruments in older adults with cLBP. This study evaluates construct (convergent and discriminant) validity and time to complete (TTC) PROMIS as compared to legacy instruments.
Methods
We enrolled older Veterans (age 60+) with cLBP with/without leg pain scheduled for lumbar epidural steroid injections. Subjects completed PROMIS computer adaptive test item banks and corresponding legacy instruments in the following domains: pain intensity, interference, and behavior; functional status; depression and anxiety; fatigue; sleep and social functioning. Convergent and discriminant validity between PROMIS and legacy instruments was evaluated using Spearman rank order correlations; Mann-Whitney U tests compared TTC.
Results
Of the 71 Veterans recruited, the median (IQR) age was 67 (63–71) years old, 94% were men, 76% were White, 17% Black, and 96% were Non-Hispanic. Spearman correlations between PROMIS and legacy instruments showed moderate to very strong convergent validity in all domains (r = 0.4–1.0), except for social functioning and pain behavior (PROMIS Pain Behavior with Fear Avoidance Belief Questionnaire). The total median TTC for all PROMIS items was significantly shorter than legacy items, 8 min 50 s vs 29 min 14 s respectively, p < 0.001.
Conclusions
Given time efficiency of using PROMIS, along with strong construct validity, PROMIS instruments are a practical choice for measuring multidimensional PROs in older Veterans with cLBP for both research and clinical purposes.
“…Also, the 3 to 6 point improvement in PROMIS depression T-scores was above the minimally important difference. This greater sensitivity of symptom scales for detecting improvement has been previously reported for depression [5,16,24], pain [20,22,[25][26][27][28] and anxiety [24].…”
Section: Discussionsupporting
confidence: 74%
“…The retrospective global rating of change assesses overall clinical response from the participant's perspective [20]. At follow-up, participants were asked to rate their mood change compared to their mood at baseline assessment.…”
Section: Retrospective Global Rating Of Changementioning
confidence: 99%
“…For the prospective anchor, we evaluated each measure's ability to detect any improvement (+ 1 to + 4) as well as moderate improvement (+ 2 to + 4). To determine if depression scales differed in their ability to detect improvement, we also statistically compared AUC values between measures [20,23].…”
Background
The PROMIS depression scales are reliable and valid measures that have extensive normative data in general population samples. However, less is known about how responsive they are to detect change in clinical settings and how their responsiveness compares to legacy measures. The purpose of this study was to assess and compare the responsiveness of the PROMIS and Patient Health Questionnaire (PHQ) depression scales in three separate samples.
Methods
We used data from three clinical trials (two in patients with chronic pain and one in stroke survivors) totaling 651 participants. At both baseline and follow-up, participants completed four PROMIS depression fixed-length scales as well as legacy measures: Patient Health Questionnaire 9-item and 2-item scales (PHQ-9 and PHQ-2) and the SF-36 Mental Health scale. We measured global ratings of depression change, both prospectively and retrospectively, as anchors to classify patients as improved, unchanged, or worsened. Responsiveness was assessed with standardized response means, statistical tests comparing change groups, and area-under-curve analysis.
Results
The PROMIS depression and legacy scales had generally comparable responsiveness. Moreover, the four PROMIS depression scales of varying lengths were similarly responsive. In general, measures performed better in detecting depression improvement than depression worsening. For all measures, responsiveness varied based on the study sample and on whether depression improved or worsened.
Conclusions
Both PROMIS and PHQ depression scales are brief public domain measures that are responsive (i.e., sensitive to change) and thus appropriate as outcome measures in research as well as for monitoring treatment in clinical practice.
Trial registration ClinicalTrials.gov ID: NCT01236521, NCT01583985, NCT01507688
“…The reliability and validity of PROMIS physical functioning and pain interference measures have been established in several pain populations, 1 , 2 , 4 , 5 , 24 , 51 and emerging studies are demonstrating the responsiveness of the short-form versions of these measures. 16 , 17 , 84 Furthermore, there is now a crosswalk table available to transform the BPI pain interference scores to PROMIS pain interference short-form scores 5 (crosswalks for scores from other PROMIS and legacy measures are available at http://www.prosettastone.org/Pages/default.aspx .)…”
Section: Review Of Clinical Outcome Assessments For Chronic Painmentioning
Clinical outcome assessments (COAs) measure outcomes that are meaningful to patients in clinical trials and are critical for determining whether a treatment is effective. The objectives of this study are to (1) describe the different types of COAs and provide an overview of key considerations for evaluating COAs, (2) review COAs and other outcome measures for chronic pain treatments that are recommended by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) or other expert groups, and (3) review advances in understanding pain-related COAs that are relevant to clinical trials. The authors reviewed relevant articles, chapters, and guidance documents from the European Medicines Agency and U.S. Food and Drug Administration. Since the original core set of outcome measures were recommended by IMMPACT 14 years ago, several new advancements and publications relevant to the measurement or interpretation of COAs for chronic pain trials have emerged, presenting new research opportunities. Despite progress in the quality of measurement of several outcome domains for clinical trials of chronic pain, there remain some measurement challenges that require further methodological investigation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.